Adjuvant trastuzumab in HER2-positive breast cancer.

The New England journal of medicine

Volumn 365, Issue 14, 2011, Pages 1273-1283

  Slamon, Dennis ^a   Eiermann, Wolfgang ^b   Robert, Nicholas ^b   Pienkowski, Tadeusz ^b   Martin, Miguel ^b   Press, Michael ^b   Mackey, John ^b   Glaspy, John ^b   Chan, Arlene ^b   Pawlicki, Marek ^b   Pinter, Tamas ^b   Valero, Vicente ^b   Liu, Mei Ching ^b   Sauter, Guido ^b   von Minckwitz, Gunter ^b   Visco, Frances ^b   Bee, Valerie ^b   Buyse, Marc ^b   Bendahmane, Belguendouz ^b   Tabah Fisch, Isabelle ^b   Lindsay, Mary Ann ^b   Riva, Alessandro ^b   Crown, John ^b   Breast Cancer International Research Group, ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HEART FAILURE; HEART STROKE VOLUME; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKEMIA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE; HUMANS; INTENTION TO TREAT ANALYSIS; LEUKEMIA; MIDDLE AGED; RECEPTOR, ERBB-2; STROKE VOLUME; SURVIVAL RATE;

EID: 80053539103     PISSN: None     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0910383     Document Type: Article

References (0)